Tobacco Use Disorder Clinical Trial
Official title:
Nicotine Patch Pre-treatment for Smoking Cessation in PTSD
This study seeks to evaluate the relationship between PTSD, abstinence, and factors associated with relapse in the context of a randomized, clinical smoking cessation trial.
Smokers with PTSD will be randomly assigned to 1 of 2 pre-cessation patch therapy conditions
(active patch versus placebo patch) for three weeks before a target quit-smoking date. All
participants to will receive bupropion beginning 1 week prior to their quit day, given that
they are medically eligible to be prescribed bupropion. All participants will receive a two
session brief cognitive-behavioral therapy (CBT) session and will begin standard nicotine
replacement therapy (NRT) on their quit day. PTSD symptoms, mood, and smoking craving will
be carefully evaluated throughout the study using electronic diary assessments on personal
digital assistants (PDA). Specifically, participants will carefully monitor their symptoms,
mood, craving, and use of cigarettes using electronic diaries for one week prior to the
pre-cessation period, during the 3-week pre-cessation treatment period, and 6 weeks post
quit date. Since no previous study has examined factors associated with smoking abstinence
following treatment among PTSD smokers10, predictors of treatment response will be examined.
The study is designed to address the following items:
Specific Aim 1: To evaluate whether supplemental nicotine administration (i.e.,
pre-cessation treatment with nicotine patch and bupropion) will result in improved quit
rates among smokers with PTSD.
Hypothesis 1.1 Supplemental nicotine administration during the pre-cessation period will
result in improved quit rates in the first quit week over the placebo patch condition.
Specific Aim 2: To utilize electronic diary assessment of PTSD symptoms, mood, smoking
craving, and smoking during baseline, pretreatment, and quit periods to evaluate potential
mechanisms of how pretreatment with the nicotine patch may increase abstinence rates.
Hypothesis 2.1 Supplemental nicotine administration will decrease craving for cigarettes
during the 2 week pretreatment period as compared to the placebo patch condition.
Hypothesis 2.2 Supplemental nicotine administration will decrease the perceived improvement
in mood and PTSD symptoms associated with smoking behavior, i.e., symptom relief from ad lib
smoking a cigarette will be reduced during supplemental nicotine administration as compared
to the placebo patch condition.
Specific Aim 3: To investigate potential predictors of smoking abstinence and relapse
associated with individual differences in affective style including anxiety sensitivity,
measures of distress tolerance, and self-efficacy.
Hypothesis 3.1 Increased anxiety sensitivity will be predictive of shorter abstinence from
smoking.
Hypothesis 3.2 Decreased distress tolerance will be predictive of shorter abstinence.
Hypothesis 3.3 Lower self-efficacy for smoking abstinence will be predictive of shorter
abstinence.
Hypothesis 3.4 Increased PTSD symptoms severity and negative affect following the quit date
will be associated with shorter abstinence.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02432066 -
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
|
Phase 2 | |
Completed |
NCT03960138 -
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Completed |
NCT04646668 -
Comparative Abuse Liability Among African American and White Smokers
|
N/A | |
Completed |
NCT02560324 -
Effect of Ramelteon on Smoking Abstinence
|
Phase 2 | |
Completed |
NCT02347605 -
Medicinal Nicotine for Preventing Cue Induced Craving
|
N/A | |
Completed |
NCT01625767 -
Tobacco Approach Avoidance Training for Adolescent Smokers-1
|
Phase 2 | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Terminated |
NCT01800500 -
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
|
N/A | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT01337817 -
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
|
Phase 1 | |
Completed |
NCT00967005 -
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
|
Phase 2 | |
Active, not recruiting |
NCT00751660 -
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers
|
N/A | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00664261 -
Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
|
N/A | |
Completed |
NCT00134927 -
A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches
|
N/A | |
Completed |
NCT00158145 -
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
|
Phase 2 | |
Completed |
NCT01213524 -
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
|
Phase 2 |